|
Oxcarbazepine is used alone or with other medications to treat seizure disorders (epilepsy). The product will be manufactured at the group's formulation manufacturing facility in Baddi, Himachal Pradesh (India).
Accroding to IQVIA MAT May 2023, Oxcarbazepine tablets had annual sales of $105 million in the United States.
The group now has 374 approvals and has so far filed over 442 ANDAs since the commencement of the filing process in FY 2003-04.
Zydus Lifesciences is a discovery-driven, global lifesciences company that discovers, develops, manufactures, and markets a broad range of healthcare therapies.
The company's consolidated net profit (from continuing operations) tumbled 27.55% to Rs 298.8 crore despite of 31.66% jump in total revenue from operations to Rs 5,010.6 crore in Q4 FY23 over Q4 FY22.
The scrip declined 1.04% to currently trade at Rs 572.30 on the BSE.
|